S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
NYSE:TARO

Taro Pharmaceutical Industries - TARO Earnings Date, Estimates & Call Transcripts

$30.41
-0.17 (-0.56%)
(As of 02/3/2023 09:05 PM ET)
Add
Compare
Today's Range
$29.74
$30.56
50-Day Range
$27.88
$31.59
52-Week Range
$27.50
$51.08
Volume
7,000 shs
Average Volume
9,813 shs
Market Capitalization
$1.14 billion
P/E Ratio
24.93
Dividend Yield
N/A
Price Target
$35.00
Skip Charts & View Estimated and Actual Earnings Data

TARO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TARO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Taro Pharmaceutical Industries Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20231$0.23$0.23$0.23

TARO Earnings Date and Information

Taro Pharmaceutical Industries has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 25th, 2023 based off prior year's report dates.

Taro Pharmaceutical Industries Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/25/2023
(Estimated)
        
10/27/2022Q2 2023$0.84($0.07)($0.91)($0.07)$161.02 million$130.50 million
7/27/2022Q1 2023$0.85$0.37($0.48)$0.37$149.90 million$156.67 million
5/26/2022Q4 2022$0.88$0.73($0.15)$0.73$147.00 million$143.26 million
1/27/2022Q3 2022$0.70+$0.70$0.70$138.98 million    
10/28/20219/30/2021$1.02$0.66($0.36)$0.70$153.23 million$131.99 million
7/27/20216/30/2021$0.84$1.09+$0.25$2.68$137.20 million$147.11 million
5/18/2021Q4$0.92($0.78)($1.70)$2.40$147.33 million$148.35 million
1/27/202112/31/2020$1.01$0.86($0.15)$0.86$152.63 million$140.15 million
10/28/20209/30/2020$0.77$1.18+$0.41$1.18$125.30 million$142.84 million  
7/29/20206/30/2020$1.16($11.37)($12.53)$12.89$158.35 million$117.63 million
5/19/20203/31/2020$1.53$1.42($0.11)$1.42$168.25 million$174.94 million  
2/3/2020Q3$1.54$1.76+$0.22$1.76$172.00 million$147.68 million
11/4/2019Q2$1.72$1.46($0.26)$1.46$168.60 million$160.85 million  
8/8/2019Q1$1.96$1.72($0.24)$1.72$169.80 million$161.30 million
5/22/2019Q4$2.26$1.52($0.74)$1.52$189.90 million$179.92 million  
2/6/2019Q3 2019$1.95$2.40+$0.45$2.40$174.70 million$176.38 million
11/5/20189/30/2018$1.96$1.60($0.36)$1.60$167.40 million$158.97 million
8/9/20186/30/2018$2.33$1.71($0.62)$1.71$179.54 million$154.62 million
5/17/20183/31/2018$1.51$2.17+$0.66$2.17$166.59 million$175.22 million  
2/7/2018Q3 2018$1.37+$1.37$2.29$155.46 million
11/7/2017Q2 2018$1.30+$1.30$1.30$169.92 million
8/8/2017Q1 2018$1.35+$1.35$1.35$161.32 million
5/22/2017Q4$2.05+$2.05$2.05$196.41 million
2/9/2017Q3 2017$3.42+$3.42$3.42$220.40 million
11/8/2016Q2 2017$3.00+$3.00$3.00$228.79 million  
8/10/2016Q1 2017$2.59+$2.59$2.59$215.30 million$233.80 million
5/26/2016Q4 2016$2.68+$2.68$2.68$265.07 million  
2/10/2016Q3 2016$4.41+$4.41$4.41$974.38 million$258.30 million
11/3/2015Q2 2016$3.11+$3.11$3.11$212.06 million
8/6/2015Q1 2016$2.42+$2.42$2.42$1.01 billion$215.30 million
5/26/2015Q4 2015$3.56+$3.56$3.56$881.79 million$244.18 million  
2/10/2015Q3 2015$3.33+$3.33$3.33$213.60 million$237.70 million
11/9/2014Q2 2015$3.35+$3.35$3.35$250.83 million
8/7/2014Q1 2015$0.98+$0.98$0.88$130.23 million
5/27/2014Q4 2014$2.10+$2.10$2.10$165.13 million$187.20 million
2/10/2014Q3 2014$2.59+$2.59$2.59$185.70 million$213.60 million
11/12/2013Q2 2014$2.15+$2.15$2.15$205.32 million
8/7/2013Q1 2014$1.32+$1.32$1.32$159.15 million$153.20 million
5/23/2013Q4 2013$1.45+$1.45$1.80$145.00 million$165.10 million
2/4/2013Q3 2013$1.98+$1.98$1.98
11/1/2012Q213$1.46+$1.46$138.25 million$160.97 million
8/6/2012Q1 2013$1.41+$1.41$1.41
5/24/2012Q4 2012$1.06+$1.06$1.06
2/10/2012Q3 2012$1.42+$1.42$1.44
11/10/2011Q2 2012$1.31+$1.31$1.30
7/26/2011Q1 2012$0.81+$0.81$0.82
5/26/2011Q4 2011$0.58+$0.58$0.58
1/28/2011Q3 2011$0.11+$0.11$0.11
10/29/2010Q2 2011$0.46+$0.46$0.46
8/23/2010Q1 2011$0.46+$0.46$0.46
6/14/2010Q4 2010$0.25+$0.25$0.25
12/2/2009Q2 2010$0.24+$0.24$0.24
8/10/2009Q1 2010$0.31+$0.31$0.31
5/22/2009Q4 2009$0.27+$0.27$0.27
2/10/2009Q3 2009$0.65+$0.65$0.85
11/11/2008Q2 2009$0.31+$0.31$0.31












Taro Pharmaceutical Industries Earnings - Frequently Asked Questions

When is Taro Pharmaceutical Industries's earnings date?

Taro Pharmaceutical Industries has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 25th, 2023 based off last year's report dates. Learn more on TARO's earnings history.

How much revenue does Taro Pharmaceutical Industries generate each year?

Taro Pharmaceutical Industries (NYSE:TARO) has a recorded annual revenue of $561.35 million.

How much profit does Taro Pharmaceutical Industries generate each year?

Taro Pharmaceutical Industries (NYSE:TARO) has a recorded net income of $58.27 million. TARO has generated $1.22 earnings per share over the last four quarters.

What is Taro Pharmaceutical Industries's price-to-earnings ratio?

Taro Pharmaceutical Industries (NYSE:TARO) has a trailing price-to-earnings ratio of 24.93 and a forward price-to-earnings ratio of 42.24.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NYSE:TARO) was last updated on 2/6/2023 by MarketBeat.com Staff